Sonnet BioTherapeutics Announces Webcast to Discuss Interim Data from the Company's Phase 1 Dose-Escalation Trials of SON-1010 on November 2, 2022Accesswire • 11/01/22
Sonnet BioTherapeutics Announces an Agreement with Janssen for the Evaluation of Three Sonnet Product CandidatesAccesswire • 10/31/22
Sonnet BioTherapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementAccesswire • 10/04/22
Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010Accesswire • 09/21/22
Sonnet BioTherapeutics Provides Fiscal Year 2022 Third Quarter Business and Earnings UpdateAccesswire • 08/15/22
Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral NeuropathyAccesswire • 07/22/22
Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy VolunteersAccesswire • 07/21/22
Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint InhibitionAccesswire • 06/09/22
Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of QuorumAccesswire • 06/02/22
Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings UpdateAccesswire • 05/10/22
Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid TumorsAccesswire • 04/13/22
Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American Association for Cancer Research (AACR) 2022 Annual MeetingAccesswire • 04/08/22
Sonnet BioTherapeutics Announces FDA Clearance of Its IND for SON-1010 for the Treatment of Advanced Solid TumorsAccesswire • 03/16/22